Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE
- PMID: 27733759
- DOI: 10.1038/nrrheum.2016.158
Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE
Abstract
New insights into the mechanisms of autoimmune diseases have been obtained not only from preclinical studies, but also from clinical trials of pan-B-cell-directed therapy. Overall, the results of these clinical trials suggest that more-specific approaches focusing on pathogenic B-cell functions, and perhaps sparing or even enhancing regulatory B-cell activity, might be attractive alternatives. Importantly, pathogenic B-cell subpopulations function within a network of cellular interactions, many of which might require additional interventions to restore immunologic balance and suppress autoimmune disease. Thus, approaches that simultaneously target innate immune cells as well as multiple nodes of T-cell and B-cell interactions might hold the promise of improved therapeutic efficacy. Interfering with B-cell intracellular signalling pathways, altering their intracellular metabolic pathways and perturbing transcription factors are additional options. This Review critically analyses these approaches, examines the role of cytokines and other functions of B-lineage cells separate from antibody secretion, and provides insights into the potential next generation of therapies targeting B-lineage cells.
Similar articles
-
B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.Nat Clin Pract Rheumatol. 2006 Jan;2(1):20-7. doi: 10.1038/ncprheum0042. Nat Clin Pract Rheumatol. 2006. PMID: 16932648 Review.
-
New treatments for SLE: cell-depleting and anti-cytokine therapies.Best Pract Res Clin Rheumatol. 2005 Oct;19(5):859-78. doi: 10.1016/j.berh.2005.05.006. Best Pract Res Clin Rheumatol. 2005. PMID: 16150407 Review.
-
Belimumab therapy in systemic lupus erythematosus.BioDrugs. 2013 Jun;27(3):225-35. doi: 10.1007/s40259-013-0031-8. BioDrugs. 2013. PMID: 23568179 Review.
-
New therapeutic avenues in SLE.Best Pract Res Clin Rheumatol. 2015 Dec;29(6):794-809. doi: 10.1016/j.berh.2016.02.007. Epub 2016 Apr 11. Best Pract Res Clin Rheumatol. 2015. PMID: 27107514 Review.
-
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.J Autoimmun. 2014 Nov;54:60-71. doi: 10.1016/j.jaut.2014.06.002. Epub 2014 Jun 21. J Autoimmun. 2014. PMID: 24958634 Review.
Cited by
-
Autoimmunity and organ damage in systemic lupus erythematosus.Nat Immunol. 2020 Jun;21(6):605-614. doi: 10.1038/s41590-020-0677-6. Epub 2020 May 4. Nat Immunol. 2020. PMID: 32367037 Free PMC article. Review.
-
Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission.Front Med (Lausanne). 2020 Apr 7;7:85. doi: 10.3389/fmed.2020.00085. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32318574 Free PMC article.
-
New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.Arthritis Rheumatol. 2017 Aug;69(8):1552-1559. doi: 10.1002/art.40109. Epub 2017 Jun 16. Arthritis Rheumatol. 2017. PMID: 28371318 Free PMC article. No abstract available.
-
Selenium supplementation suppresses immunological and serological features of lupus in B6.Sle1b mice.Autoimmunity. 2019 Mar;52(2):57-68. doi: 10.1080/08916934.2019.1603297. Epub 2019 Apr 22. Autoimmunity. 2019. PMID: 31006265 Free PMC article.
-
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.Patient Relat Outcome Meas. 2019 Jan 9;10:1-7. doi: 10.2147/PROM.S134326. eCollection 2019. Patient Relat Outcome Meas. 2019. PMID: 30666173 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical